FDA Urges Guillain-Barré Syndrome Warning On Labels Of RSV …
1 day ago · Meanwhile, GlaxoSmithKline's Arexvy reported sales of 188 million pounds in the third quarter of 2024, compared to 700 million pounds in the third quarter of 2023.
FDA Alert: FDA Requires Guillain-Barré Syndrome (GBS) Warning …
3 days ago · Arexvy was initially approved on May 3, 2023, for the prevention of LRTD caused by RSV in individuals 60 years of age and older. ... Subscribe to our newsletter for the latest medication news, new drug approvals and FDA alerts. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter ...
New data for Arexvy, GSK’s respiratory syncytial virus vaccine, …
Oct 24, 2024 · GSK plc (LSE/NYSE: GSK) today announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due to certain underlying medical conditions and in adults who are immunocompromised.
RSV Vaccine Labeling Updated With Guillain-Barré Syndrome …
1 day ago · Arexvy is indicated for active immunization for the prevention of LRTD caused by RSV in individuals 60 years and older, and those 50 through 59 years old at increased risk for LRTD caused by RSV ...
GSK presents positive data for AREXVY, its respiratory syncytial …
Oct 8, 2024 · AREXVY is the world’s first RSV vaccine and was approved based on exceptional efficacy in adults aged 60 and older including those who are at increased risk due to certain underlying medical conditions.
FDA Requires Warning for Guillain-Barré Syndrome in Prescribing ...
3 days ago · The FDA has also required GSK to conduct a study evaluating the risk of GBS among 1.9 million adults 50 years of age and older vaccinated with Arexvy. 1 “FDA has further determined that the benefits of vaccination with Abrysvo and Arexvy continue to outweigh their risks,” the news release said.
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, …
PHILADELPHIA, October 24, 2024 -- (BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49...
GSK Presents Positive Data for AREXVY, Its Respiratory
Oct 8, 2024 · AREXVY is the world’s first RSV vaccine and was approved based on exceptional efficacy in adults aged 60 and older including those who are at increased risk due to certain underlying...
New Data for Arexvy Show Vaccine Efficacy Through 3 RSV …
Oct 9, 2024 · A single dose of the GSK vaccine Arexvy against respiratory syncytial virus (RSV) showed positive safety and efficacy data for protection over 3 RSV seasons for adults aged 60 years and older, including those at increased risk of severe disease, according to a company announcement. 1
Arexvy Looks Promising for RSV Protection in Younger At-Risk …
Nov 4, 2024 · New data for Arexvy, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease. News release. GSK. October 24, 2024.